← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Corixa Corporation
Hamilton, MT
$37,059,568
Total funding
19
Grants
Funding over time
peak $10.6M · FY2005–14$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$37,059,568 · 19
By mechanism
N01$27,271,873 · 3
UC1$5,007,617 · 2
R44$3,425,546 · 6
R37$557,134 · 1
R43$399,968 · 4
R01$277,726 · 1
Investigators at Corixa Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Adjuvant discovery: lipid A mimetics$8,318,730
N01 · FY2009 · AI
Novel TLR7/8 agonists as adjuvants for rapid-acting vaccines$6,018,893
N01 · FY2011 · AI
Identification of novel Th17 inducing CTLR agonists for vaccines against mycobacterium tuberculosis$5,082,137
N01 · FY2014 · AI
Novel TLR7/8 agonists as adjuvants for rapid-acting vaccines$3,750,387
N01 · FY2013 · AI
Rapid Acting Vaccine for Pandemic Influenza$2,691,277
UC1 · FY2005 · AI
Development of a Recombinant Tuberculosis Vaccine$2,316,340
UC1 · FY2000 · AI
Novel TLR7/8 agonists as adjuvants for rapid-acting vaccines$2,308,292
N01 · FY2009 · AI
Novel TLR7/8 agonists as adjuvants for rapid-acting vaccines$1,078,434
N01 · FY2012 · AI
Adjuvant Development$715,000
N01 · FY2013 · AI
PRE-CLINICAL DEVELOPMENT OF NOVEL HSV-2 ANTIGENS$386,573
R44 · FY2003 · AI
NOVEL GENES FOR THE DIAGNOSIS/PROGNOSIS OF BREAST CANCER$384,937
R44 · FY2000 · CA
NOVEL MARKERS FOR PROSTATE CANCER DIAGNOSIS/PROGNOSIS$382,832
R44 · FY2001 · CA
NOVEL GENES FOR THE DIAGNOSIS/PROGNOSIS OF BREAST CANCER$382,109
R44 · FY2001 · CA
NOVEL ANTIGENS FOR THE SERODIAGNOSIS OF HUMAN BABESIOSIS$377,359
R44 · FY2000 · AI
SYNTHETIC MONOSACCHARIDES ADJUVANTS FOR HUMAN VACCINES$374,959
R44 · FY2000 · AI
PRE-CLINICAL DEVELOPMENT OF NOVEL HSV-2 ANTIGENS$363,407
R44 · FY2004 · AI
VACCINE FOR LEISHMANIASIS$352,372
R44 · FY2000 · AI
NOVEL MARKERS FOR PROSTATE CANCER DIAGNOSIS/PROGNOSIS$285,998
R44 · FY2002 · CA
SPECIFIC IMMUNOTHERAPY OF MURINE TUMORS$278,567
R37 · FY2002 · CA
SPECIFIC IMMUNOTHERAPY OF MURINE TUMORS$278,567
R37 · FY2000 · CA